FDA okays Powerheart for use outside hospitals:
This article was originally published in Clinica
Cardiac Science says it has received a notification from the FDA that allows it to sell its fully automated Powerheart defibrillator-monitor for out-of-hospital applications in the US. The system, which was cleared by the FDA for hospital-use last year, prophylactically monitors cardiac patients for the detection of life-threatening heart rhythms and delivers defibrilliation shocks within seconds without human intervention. It can now be used in outpatient or doctors' office settings, says the Irvine, California company.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.